🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lorenza Rimassa

Humanitas University

ORCID: 0000-0001-9957-3615

Also affiliated with IRCCS Humanitas Research Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 6 papers. Top paper: “Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma”.

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.02.005
N/A
0.868DataRank · unranked
326 citations

S.L. Chan, R.K. Kelley, G. Lau, M. Kudo, W. Sukeepaisarnjaroen +198 more

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

European Journal of Cancer(2022)10.1016/j.ejca.2022.08.024
N/A
0.709DataRank · unranked
112 citations

Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron +32 more

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

JHEP Reports(2025)10.1016/j.jhepr.2025.101685
N/A
0.165DataRank · unranked
2 citations

Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li +36 more

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Hepatology Communications(2023)10.1097/hc9.0000000000000302
N/A
0DataRank · unranked
11 citations

Bernhard Scheiner, Antonio D ́Alessio, Claudia Angela Maria Fulgenzi, Martin Schönlein, Lorenz Kocheise +31 more

Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry

International Journal of Infectious Diseases(2023)10.1016/j.ijid.2023.11.021
N/A
0DataRank · unranked
3 citations

Samuel Minkove, Isabel Ruíz-Camps, Simeón Eremiev, Gino M Dettorre, María Laura Fox +39 more

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab

JHEP Reports(2024)10.1016/j.jhepr.2024.101295
N/A
0DataRank · unranked
9 citations

Philipp Mildenberger, Jennifer Gile, Fabian Jost‐Brinkmann, Bernhard Scheiner, Catherine Leyh +54 more